New drug shows promise in controlling blood cancer

A new drug called rusfertide has shown promising results in a clinical trial for polycythemia vera, a rare and life-threatening blood cancer. The drug lowered the excess production of red blood cells, the main cause of the disease and its serious complications.
The trial, led by researchers from the Icahn School of Medicine at Mount Sinai, involved 70 patients who were dependent on phlebotomy, a procedure that removes blood from the body to reduce its volume. The patients received rusfertide injections for 28 weeks and were monitored for their blood counts and symptoms.